Tristin Mc Guffick
About Tristin Mc Guffick
Tristin Mc Guffick is the Associate Director of Technology Transfers and Project Management at Capricor Therapeutics, Inc., where he has worked since 2015. He holds a Master's degree in Biomedical/Medical Engineering from California Polytechnic State University-San Luis Obispo and has extensive experience in coordinating technology transfer activities and contributing to clinical trial manufacturing processes.
Work at Capricor Therapeutics
Tristin Mc Guffick has served as the Associate Director of Technology Transfers and Project Management at Capricor Therapeutics, Inc. since 2015. In this role, he coordinates technology transfer activities for various projects, including a phase II manufacturing process to a Contract Manufacturing Organization (CMO). His responsibilities include overseeing the manufacturing components of Investigational New Drug (IND) submissions for clinical trials, specifically focusing on cell therapy. He has also acted as a Subject Matter Expert (SME) for the manufacturing process during technology transfers.
Education and Expertise
Tristin Mc Guffick holds a Master's degree in Biomedical/Medical Engineering from California Polytechnic State University-San Luis Obispo. He also earned a Bachelor's degree in the same field from the same institution. His educational background provides a strong foundation for his expertise in technology transfers and project management within the biotechnology sector.
Background
Before joining Capricor Therapeutics, Tristin Mc Guffick worked as an Order Processor at Running Warehouse from 2013 to 2015 in the San Luis Obispo, California area. This role provided him with experience in operational processes, which he later applied to his current position in the biotechnology industry. His transition to Capricor Therapeutics marked a significant shift towards a focus on technology transfer and project management in the life sciences.
Achievements
In his current role, Tristin Mc Guffick has contributed to critical aspects of the manufacturing process for a phase II clinical trial in cell therapy. He has reviewed module 3 of the IND submission, implemented corrective and preventive actions for manufacturing processes, and supervised the documentation of manufacturing deviations. Additionally, he has conducted root cause investigations to enhance manufacturing efficiency and compliance.